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L’Association pour la
recherche sur le cancer
Otherwise known as … l’ARC
(pronounced ‘lark’).
What is it famous for? Being one of
France’s largest medical research
charities and the best known, as far
as the French public is concerned,
because of its strong media presence.
Does it have much money to give away?
L’ARC’s income in 1999 was
FFr317 million (£32 million), three
quarters of which went into funding
research. Although this might not
seem a lot, l’ARC — together with
the other major French cancer
charity, La Ligue Nationale Contre le
Cancer (LNCC) — has an important
role in plugging the gaps left by the
stagnant budgets of CNRS and
INSERM, France’s public research
agencies. Indeed, there are few
biomedical scientists in France who
have not benefited from l’ARC
funding at one time or another.
So it’s not all ‘cancer research’ then?
L’ARC is considered very progressive
and is known for its willingness to
fund basic research that might seem
far-removed from the cancer patient.
To give an idea of l’ARC’s breadth of
coverage, this journal published 15
research articles that originated from
French labs last year; 11 of these, with
subject material ranging from neuron
specification in frogs to blastomere
fate in the zebrafish, acknowledged
l’ARC for part-funding.
What else does l’ARC spend its money
on? Last year, 410 stipends for
graduate students and postdocs were
disbursed by l’ARC to the tune of
FFr50.6 million (£5.2 million). These
stipends, or bourses, are hard to come
by in France and l’ARC’s support in
this area is seen as a lifeline,
particularly as French graduate
students almost invariably take four
years to complete their doctoral
studies, and government support
lasts only three years.
Where does the money come from?
L’ARC raises almost all its money
from public donations and legacies,
relying heavily on its media
presence. The charity is firmly
associated in the public mind with
the founder of l’ARC, Jacques
Crozemarie (or Crozy as he is
familiarly known), who until recently
made regular televised appeals (in a
white lab coat, although he has never
been a physician or scientist).
Advertisements in the press have
been accompanied by signed
photographs of Crozy.
How did l’ARC begin? L’ARC’s
forerunner, created in 1962 by
Crozemarie, was the fund-raising
body for the Institut Gustave-Roussy
and several other cancer research labs
based in the Paris suburb of Villejuif.
It became a national charity in 1979
and since then has been the subject
of some well-publicised controversies.
Why is it in the news? Crozemarie is
alleged to have embezzled
FFr300 million (£30.6 million) of the
charity’s funds. He appeared in court
in June — along with 25
others — accused of diverting the
funds into Swiss bank accounts
through an elaborate scheme of false
and inflated invoices. The scandal,
which was made public in December
1994, has been described by the
French media as “the biggest racket
involving a charity this century.” In
1993, before its name fell into
disrepute, l’ARC’s income was
FFr581.2 million (£59.3 million). But
according to France’s national audit
commission, which has been
investigating the charity’s accounts,
less than one-third of l’ARC’s income
was spent funding research in 1993.
Public generosity towards medical
charities in general dropped sharply
when the scandal broke. 
Has l’ARC recovered? The installation
of Michael Lucas — the former head
of the watchdog body that exposed
the financial irregularities of the
charity — as the new president of
l’ARC in 1996 and a purge of l’ARC’s
administrative council, seem to have
helped rebuild public confidence, if
the steady increase in donations is
anything to go by.
What will happen to Crozemarie? He
could face imprisonment for up to
five years but his fate hangs in the
balance as the French judiciary, like
the rest of the country, grinds to a
halt for the summer holidays.
Primer
Human memory
Alan J. Parkin
At one level we can say that we know
exactly what human memory
is — the learning of new information
involves changes in the synaptic
connections between neurons
specialised for the storage of
information. This is known from in
vivo studies of simple invertebrates
and there is no reason to suppose
that these fundamental mechanisms
do not also apply to humans. We also
know which regions of the brain are
specialized for memory and that
various neurotransmitters are
involved in memory, notably
acetylcholine, the neurotransmitter
known to be massively depleted in
Alzheimer’s disease.
But how does this anatomical and
physiological knowledge enable us to
understand the different types of
memory, or how any given piece of
knowledge is derived from a
particular combination of synaptic
connections? Quite simply we have
no idea at present and for this reason
we have to think of memory at two
levels: biological and psychological.
Eventually, the two sources of
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